オプションチェーンは、Checkpoint Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Checkpoint Therapeuticsの市場センチメントを評価します。.

Checkpoint Therapeutics (NASDAQ:CKPT) 株価情報, オプションチェーン

CHECKPOINT THERAPEUTICS INC

Checkpoint Therapeutics

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics Inc

Evercore ISI Group analyst Jonathan Chappell maintains Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) with a In-Line and lowers the price target from $137 to $136.

News

Price Target

Analyst Ratings

LSTR

Evercore ISI Group Maintains In-Line on Landstar System, Lowers Price Target to $136

Evercore ISI Group maintains Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) with a Outperform and lowers the price target from $35 to $32.

FLOC

Evercore ISI Group Maintains Outperform on Flowco Holdings, Lowers Price Target to $32

Needham analyst John Todaro maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $58 to $71.

HOOD

Needham Maintains Buy on Robinhood Markets, Raises Price Target to $71

Trading Ideas

GRFX

Graphex Group Shares Halted, News Pending

Evercore ISI Group analyst Mark Lipacis maintains Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Outperform and lowers the price target from $100 to $82.

CAMT

Evercore ISI Group Maintains Outperform on Camtek, Lowers Price Target to $82

Evercore ISI Group analyst Cory Kasimov initiates coverage on Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Outperform rating and announces Price Target of $55.

Initiation

XENE

Evercore ISI Group Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating, Announces Price Target of $55

Seaport Global analyst Bill Ryan initiates coverage on Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Buy rating and announces Price Target of $124.

ENVA

Seaport Global Initiates Coverage On Enova International with Buy Rating, Announces Price Target of $124

Shares of On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) were climbing in early trading on Wednesday after the company reported its <a href="https://www.benzinga.com/markets/equities/25/05/45397896/roger-federer-backed-on-holding-jumps-12-as-dtc-sales-soar-sneaker-price-hikes-coming-to-offset-tariffs-and-fuel-premium-growth" target="_blank" rel="noopener">first-quarter results on Tuesday</a>.
Here are some key analyst takeaways.
KeyBanc Capital Markets Reiterates Overweight
Analyst Ashley Owens reiterated an Overweight rating while raising the price target from $60 to $68.
On Holding delivered a strong beat, with revenue growth of 43% year-on-year, "driven by the successful launches of the Cloudsurfer 2 and Cloud 6, coupled with strong traction in apparel," Owens said in a note. The company's adjusted EBITDA margin expanded by 27 basis points to 16.5%, "driven by improved execution across the supply chain," he added.
Although management raised their full-year guidance, this only reflected the first-quarter beat and left the expectations for the rest of the year unchanged, the analyst stated. On Holding plans product launches and other initiatives, "aiming to increase its differentiation in the footwear space while helping to offset most of the active 10% tariff rates," he wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Needham Comments 
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846ee56ee7bf6000154d12e/tom-nikic">Analyst Tom Nikic</a> maintained a Buy rating while lifting the price target from $55 to $62.
On Holding's DTC channel grew by 42% in the quarter, "driven by increased brand awareness and successful new product introductions, along with a resonating apparel offering," Nikic said. The company indicated that trends have remained strong so far in the current quarter, he added.
Management expects the second quarter to be "really strong" for DTC, the analyst stated. "Wholesale accelerated to 39% growth in Q1 (strongest constant-FX growth since 3Q23), and unlike other footwear brands that have called out incremental caution regarding the channel for 2H, ONON has not seen a change in trend in the channel," he wrote.
ONON Price Action: At the time of publication on Wednesday, shares of On Holding had risen by 2.21% to $58.68.
Read More: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">&nbsp;3 Consumer Discretionary Stocks to Buy in a Divided Economy&nbsp;</a>
Photo: Shutterstock

Analyst Color

Earnings Beats

Reiteration

Movers

ONON

On Holding AG Posts Strong Q1 Beat, 'Strong Traction' Among Footwear Brands, Analysts Raise Price Target

Evercore ISI Group initiates coverage on Centrus Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LEU#AMEX">LEU</a>) with a Outperform rating and announces Price Target of $145.

Evercore ISI Group Initiates Coverage On Centrus Energy with Outperform Rating, Announces Price Target of $145

Canaccord Genuity analyst Michael Walkley maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Hold and lowers the price target from $43 to $39.

Canaccord Genuity Maintains Hold on Rapid7, Lowers Price Target to $39

Stifel analyst Jim Duffy maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Buy and lowers the price target from $11 to $10.

Stifel Maintains Buy on Under Armour, Lowers Price Target to $10

Smartphone makers like Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) are hoping that consumers will trade in their phones for <a href="https://www.benzinga.com/tech/25/04/44850406/apples-foldable-iphone-rumors-gain-steam-as-stock-slides-could-a-2000-device-spark-a-comeback">new ones in the next year</a>, an item that could lock in additional revenue and higher margins.
A new Benzinga poll finds that the percentage of people who have upgraded their phones in the last 12 months is below 50%.
What Happened: Analysts highlight that users upgrading their Apple iPhones could help the technology giant boost <a href="https://www.benzinga.com/news/earnings/25/05/45152493/apple-reports-strong-q2-earnings-revenue-beat-eps-beat-installed-base-hits-all-time-high-across-all-segments-100-billion-buyback-and-more">its annual revenue</a> after releasing the iPhone 16 in September 2024 and getting ready to release the iPhone 17 in the future.
Benzinga polled readers to find out where they stand in the upgrade cycle.
"Which of the following describes your smartphone currently?" Benzinga asked.
Here were the results:
<ul class="wp-block-list">
<li>I own an iPhone and have not gotten a new phone in the last 12 months: 38%</li>
<li>I own an iPhone and got a new phone in the last 12 months: 22%</li>
<li>I own a different smartphone and have gotten a new phone in the last 12 months: 17%</li>
<li>I own a different smartphone and have not gotten a new phone in the last 12 months: 15%</li>
<li>I don't own a smartphone: 8%</li>
</ul>
The poll found that 53.5% of consumers have not upgraded their smartphones in more than 12 months, or an even higher percentage if stripping out the 8% who answered that they don't own a smartphone. The poll found that 38.6% of respondents have upgraded their smartphones in the last 12 months.
Another important finding in the poll was the strong brand power that Apple commands, with 60.4% of the users answering the question saying they own an iPhone.
Read Also: <a href="https://www.benzinga.com/tech/25/05/45357613/china-tariff-de-escalation-biggest-winners-include-tesla-apple-new-tech-highs-back-on-the-table-now-for-2025">China Tariff De-Escalation Biggest Winners Include Tesla, Apple: &#8216;New Tech Highs Back On The Table Now For 2025&#8217;</a>
Why It's Important: The fact that over 50% of users said they have not upgraded their smartphone in more than 12 months could bode well for Apple in the next iPhone release cycle.
Also potentially helping Apple would be the growth of AI features like Apple Intelligence with the iPhone 17. Apple Intelligence released in October 2024, a month after the iPhone 16 released.
While users could upgrade to experience Apple Intelligence, the full benefits of an upgrade cycle may not have been realized by Apple and could be hit with a new iPhone that comes standard with Apple Intelligence features.
Benzinga also asked users which feature is the most important when considering a phone upgrade.
"Which of the following is the most important reason to upgrade to a new phone?" Benzinga asked.
The results were:
<ul class="wp-block-list">
<li>Old phone feels outdated: 28%</li>
<li>Artificial intelligence features: 27%</li>
<li>Better battery life: 26%</li>
<li>Batter camera: 19%</li>
</ul>
The poll found that an outdated phone, which could mean a number of things, is the most important factor when considering an upgrade. Ranking second could be the key for Apple's future success with artificial intelligence features the second-most important reason to upgrade a smartphone.
The study was conducted by Benzinga from May 5, 2025, through May 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 316 adults.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/04/45112477/exclusive-if-meta-is-forced-to-divest-instagram-whatsapp-or-facebook-43-pick-this-standout">EXCLUSIVE: If Meta Is Forced To Divest Instagram, WhatsApp, Or Facebook, 43% Pick This Standout</a></li>
</ul>

Exclusives

Tech

AAPL

EXCLUSIVE: Apple Stock Could Benefit From Smartphone Upgrade Cycle, Poll Ranks Top Reason For Trade In (It's Not The Camera)

<a href="https://www.benzinga.com/news/25/04/44590350/courtroom-clash-no-thank-you-sparks-lawsuit-as-altman-shuts-down-musks-97-4b-bid">Elon Musk </a>is setting the stage for what could be one of the artificial intelligence industry&#8217;s biggest financial leaps. During a recent investor update on April 21, first shared with <a href="https://www.youtube.com/watch?v=XH5O_X1xG2o">CNBC</a>, Musk said he wants to assign a &#8220;proper value&#8221; to his AI startup, xAI.&nbsp;
He didn't confirm a new fundraising round, but his comment hinted at possible funding from Middle Eastern sovereign wealth funds and global investors, according to people familiar with the matter. This comes after xAI secured $6 billion in late 2024, giving the company a $50 billion valuation, <a href="https://www.forbes.com/sites/antoniopequenoiv/2024/12/23/xai-valuation-reaches-over-40-billion-after-6-billion-funding-round/">Forbes reported</a>.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
<h2 class="wp-block-heading">A Big Bet On AI Infrastructure</h2>
The $6 billion raise wasn&#8217;t for buzz—it powered the expansion of &#8220;Colossus,&#8221; xAI&#8217;s supercomputer in Memphis.&nbsp;
Colossus is built with 100,000 Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) H100 GPUs and was designed to train xAI&#8217;s large language model, Grok, and is seemingly one of the most powerful AI clusters to date.
Musk&#8217;s ambitions don&#8217;t end there. As reported by the <a href="https://www.ft.com/content/53eeadd8-8fec-4f1b-991e-642e24959e02">Financial Times</a>, Musk already has plans to deploy more than 1 million GPUs, which will require scaling up Colossus. The additional capacity would give xAI a significant edge in the generative AI race, putting it in competition with established players like OpenAI and Anthropic.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
Meanwhile, in March, xAI finalized a $33 billion all-stock merger with Musk&#8217;s other venture, X. The combination integrates xAI&#8217;s technology with X&#8217;s social media ecosystem. Musk said in an <a href="https://x.com/elonmusk/status/1905731750275510312?lang=en">X post</a> that the move will provide smarter, and more meaningful experiences to billions of people.
It also solidifies xAI's revenue stream, which industry intelligence platform <a href="https://sacra.com/c/xai/">Sacra</a> estimates at about $100 million annually, primarily from X Premium subscriptions and API services.
After the merger, Musk<a href="https://x.com/elonmusk/status/1905731750275510312"> posted on X</a>, &#8220;This combination will unlock immense potential by blending xAI&#8217;s advanced AI capability and expertise with X&#8217;s massive reach.&#8221; ​His goal? To streamline AI into everyday digital interactions.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Another layer of potential investment surfaced in July. After running a public<a href="https://x.com/elonmusk/status/1815907844434112999?s=46=PySpYjNmRDrcisnq5IFhJQ"> poll on X</a>, Musk proposed bringing a $5 billion investment from Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) into xAI to the automaker&#8217;s board.&nbsp;
The poll revealed that 67.9% of voters supported the idea of Tesla investing $5 billion in his artificial intelligence startup, xAI. The initiative could link xAI&#8217;s capabilities directly to Tesla&#8217;s self-driving software and in-vehicle AI systems.
Looking forward, Bloomberg reported that <a href="https://www.benzinga.com/news/25/04/44725803/musks-xai-aims-for-1-million-gpus-in-memphis-but-can-the-citys-grid-handle-a-27b-ai-power-surge">xAI</a> is <a href="https://www.bloomberg.com/news/articles/2025-02-14/musk-s-xai-discussing-10-billion-raise-at-75-billion-valuation">seeking </a>to raise an additional $10 billion, potentially pushing its valuation to $75 billion. the funding goal in February and would place xAI in the same financial orbit as top AI labs.
Read Next:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
</ul>
Image: Shutterstock

NVDA

TSLA

Elon Musk Wants A 'Proper Value' For xAI — After $6 Billion Raise, 100,000 GPUs, And A Quiet $100 Million Deal Most Missed

WIIM

CINT

CINT stock has given up its prior loss. CI&T shares were trading lower after the company reported worse-than-expected Q1 financial results.

Stifel analyst Jim Duffy maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $57 to $66.

Stifel Maintains Buy on On Holding, Raises Price Target to $66

Canaccord Genuity analyst Austin Moeller maintains Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a Buy and raises the price target from $21 to $21.5.

LUNR

Canaccord Genuity Maintains Buy on Intuitive Machines, Raises Price Target to $21.5

GSIW

Garden Stage Shares Halted On Circuit Breaker To The Upside, Stock Now Up 69%

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has outperformed the market over the past 5 years by 10.51% on an annualized basis producing an average annual return of 25.53%. Currently, Cencora has a market capitalization of $54.16 billion. 
Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $313.24 today based on a price of $279.60 for COR at the time of writing.
<h3>Cencora's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747237519_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Stifel analyst Stephen Willey maintains Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Hold and lowers the price target from $6 to $5.

MGNX

Stifel Maintains Hold on Macrogenics, Lowers Price Target to $5

Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) with a Buy and raises the price target from $32 to $43.

GRAL

Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $43

Press Releases

CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT

Comments

Checkpoint Therapeutics

Checkpoint Therapeutics (CKPT) オプション

Checkpoint Therapeutics (NASDAQ:CKPT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル